Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review.
OBJECTIVE
The use of dantrolene in the treatment of hyperpyrexia related to MDMA (3,4-methylenedioxymethamphetamine) is controversial, with little data available to guide clinical decision-making. Although the treatment is recommended by several poison control centres, published data are primarily in the form of case reports and animal and in vitro experiments. We conducted a systematic review to investigate the published evidence regarding the safety and benefits of dantrolene for MDMA-related hyperpyrexia in humans.


METHODS
A systematic search of Embase and MEDLINE was conducted from the earliest possible date to November 2008.


METHODS
All human trials and case reports of MDMA related hyperpyrexia were considered.


METHODS
Data were abstracted systematically and characteristics including use of dantrolene, adverse reactions attributed to dantrolene, peak temperature, complications from MDMA-related hyperpyrexia and survival were recorded.


RESULTS
Our search yielded 668 articles of which 53, reporting 71 cases of MDMA-induced hyperpyrexia, met our inclusion criteria. No clinical trials, randomized controlled trials, observational studies or meta-analyses were identified. Dantrolene was used in 26 cases. Patient characteristics were similar in the dantrolene and no dantrolene groups. The proportion of survivors was higher in the dantrolene group (21/26) than in the no dantrolene group (25/45). This difference was especially pronounced in those with extreme (≥ 42°C) and severe (≥ 40°C) fever, with a survival rate of 8 of 13 and 10 of 10, respectively, in the dantrolene group compared with 0 of 4 and 15 of 27 in the no dantrolene group. There were no reports of adverse events attributable to dantrolene with the exception of a possible association with an episode of transient hypoglycemia.


CONCLUSIONS
Our systematic review suggests that dantrolene is safe for patients with MDMA-related hyperpyrexia. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42°C) or severe (≥ 40°C) hyperpyrexia, although this conclusion must be interpreted with caution given the risk of reporting or publication bias.
Grunau
Brian E
BE
Department of Emergency Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Wiens
Matthew O
MO
Brubacher
Jeffrey R
JR
D002986:Clinical Trials as Topic; D003620:Dantrolene / Q000627:therapeutic use*; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D009125:Muscle Relaxants, Central / Q000506:poisoning*; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000506:poisoning*; D016019:Survival Analysis
D009125:Muscle Relaxants, Central; D003620:Dantrolene; D018817:N-Methyl-3,4-methylenedioxyamphetamine